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Background
Nitric oxide (NO) is a potent biological mediator and plays
an important role in cardiovascular homeostasis. Here it
activates the soluble guanylyl cyclase (sGC) that synthe-
sizes cGMP. The intracellular second messenger cGMP
regulates vascular tone, vascular permeability, modulates
inflammation and platelet reactivity. In platelets cGMP
activates platelet inhibitory pathways via PKG and thereby
inhibits platelet activation. Many cardiovascular diseases
e.g. pulmonary arterial hypertension (PAH), are associated
to a defective NO signalling. Therefore agents that stimu-
late the sGC are interesting therapeutic tools for the treat-
ment of several cardiovascular diseases.
Riociguat (Bay 63-2561) stimulates the sGC NO-
independently without the risk of nitrate tolerance.
Clinical Phase II and III studies determined the efficacy
and tolerability in pulmonary hypertension patients.
Riociguat was well tolerated and also significantly
improved exercise capacity and hemodynamic para-
meters. To further analyse the effects of riociguat on
platelet activation we tested the inhibitory effects on
functions in isolated platelets and whole blood to eluci-
date additional applications of riociguat and to estimate
adverse effects such as increased bleeding tendencies.
Results
In order to study the effects of riociguat on platelet sGC
activity we monitored the VASP phosphorylation and
cyclic nucleotides in washed platelets. Already low thera-
peutically relevant doses of 0.1 µM riociguat increased
cGMP levels and VASP phosphorylation significantly.
Consistent to these findings ADP induced platelet activa-
tion in washed platelets, as shown by platelet shape
change, aggregation and integrin activation, was signifi-
cantly impaired using low doses of riociguat. Additionally
adhesion on collagen under shear conditions is signifi-
cantly reduced in platelet riched plasma. In contrast to
that one hundred times higher concentrations of rioci-
guat were needed to obtain a significant increase of
VASP phosphorylation as well as a significant inhibition
of ADP induced aggregation in whole blood.
Conclusion
Our results indicate that riociguat treatment will not
lead to an increased bleeding tendency in pulmonary
hypertension patients. Additional possible applications
of riociguat, where targeting platelet function is benefi-
cial, might be achieved using higher doses of riociguat.
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